Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia-Reference-Cited by-同舟云学术

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia

Published:2014-05-01 Issue:18 Volume:123 Page:2791-2796
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Treon Steven P.¹²,Cao Yang¹²,Xu Lian¹²,Yang Guang¹²,Liu Xia¹²,Hunter Zachary R.¹³

Affiliation:

1. Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA;

2. Department of Medicine, Harvard Medical School, Boston, MA; and

3. Department of Pathology, Boston University School of Graduate Medical Sciences, Boston, MA

Abstract

Key Points Activating MYD88 as well as nonsense and frameshift WHIM-like CXCR4 somatic mutations are common in WM. CXCR4 NS mutations are present in aggressive cases including hyperviscosity syndrome, and MYD88 status is a determinant of survival.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/18/2791/1377047/2791.pdf

Reference22 articles.

1. How I treat Waldenström macroglobulinemia.;Treon;Blood,2009

2. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia.;Treon;N Engl J Med,2012

3. The genomic landscape of Waldenstöm’s Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis [published online ahead of print December 23, 2013].;Hunter;Blood

4. Regulation of CXCR4 signaling.;Busillo;Biochim Biophys Acta,2007

5. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling.;Busillo;J Biol Chem,2010

Cited by 329 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia;British Journal of Haematology;2024-08-19

2. Impact of Chromosomal Aberrations Detected by Chromosome Banding Analysis in Symptomatic Waldenström’s Macroglobulinemia;2024-08-17

3. Expanding CXCR4 variant landscape in WHIM syndrome: integrating clinical and functional data for variant interpretation;Frontiers in Immunology;2024-07-08

4. Clinical Validation of a Targeted Next-Generation Sequencing Panel for Lymphoid Malignancies;The Journal of Molecular Diagnostics;2024-07

5. Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems.;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29